Ulrich Bickel

Ulrich Bickel serves as Associate Dean of the Office of Sciences, Full Professor in the Department of Pharmaceutical Sciences, and Director of the TTUHSC Center for Blood-Brain Barrier Research at Texas Tech University Health Sciences Center School of Pharmacy since 2002. His leadership spans academic administration, research direction, and graduate education within the pharmaceutical sciences division.

His educational background includes:

• Doctor Medicinae (Dr. med.) from University of Ulm (1985)
• Clinical Pharmacology residency at Benjamin-Franklin Hospital of the Free University of Berlin (1991)
• German Research Foundation stipend at UCLA with Dr. William M. Pardridge (1991-1994)
• Independent laboratory at Philipps-University Marburg (1994-1999)

Bickel's research centers on blood-brain barrier (BBB) physiology with expertise in:

• Pharmacokinetic modeling of solute transport
• Anesthetic effects on BBB integrity
• Antibody-based brain delivery systems
• Neurovascular responses to disease states
• Quantitative BBB permeability assessment

His lab pioneered methods using intracerebral microdialysis and LC-MS/MS for real-time BBB permeability measurement, with applications in stroke, liver disease, and drug development.

Analysis of his 15 most recent publications (2022-2025) reveals dominant focus areas: anesthetic-BBB interactions (60% of articles), quantitative transporter analysis (25%), and novel delivery platforms (15%). Key trends include propofol/isoflurane neurotoxicity mechanisms, GLUT1 quantification methodologies, and TCRm antibody trafficking pathways - all emphasizing translational applications for CNS drug delivery.

His scientific recognition includes:

• Texas Tech University Health Sciences Center Research Achievement Award (2006)
• Deutsche Forschungsgemeinschaft Research Stipend (1994)
• Deutsche Forschungsgemeinschaft Postdoctoral Stipend (1991)

Bickel actively mentors graduate students as Doctoral Advisory Committee Chair (2015-present) and Master's Thesis Committee Chair (2019-2021). His research has secured continuous funding from:

• National Institute of Neurological Disorders and Stroke
• National Multiple Sclerosis Society
• American Heart Association
• DoD Breast Cancer Research Program

As Director of the TTUHSC Center for Blood-Brain Barrier Research, he leads multidisciplinary teams developing BBB models including microfluidic platforms and transgenic mouse systems. Current initiatives focus on nanoparticle delivery systems targeting CD31 receptors and clinical translation of BBB integrity biomarkers for neuroinflammatory conditions.